Highlights of weekly biotech stock moves

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) was up $3.77 (146%) to $6.36 last week, including a $2.70 (74%) jump on Friday after an FDA panel voted 18-4, with one abstention, that the benefit-risk profile for lorcaserin supports approval to treat obesity. The PDUFA date is June 27 (see Cover Story).

Shares of fellow obesity companies Vivus Inc. (NASDAQ:VVUS) and Orexigen Therapeutics Inc. (NASDAQ:OREX) also rose on Friday. Orexigen was up $0.64 (19%) to $3.99, while Vivus gained $2.01 to $24.70...